CorMedix Inc. underwent a change of control involving Melinta Therapeutics, LLC for $260 million in cash and $40 million worth of common shares (closed 2025-08-29).
“at the effective time of the Merger (the “Effective Time”), the Company (i) paid to the Melinta equityholders (including the Consenting Melinta Members) an aggregate of $260 million in cash (subject to adjustment for the Aggregate Exercise Price, Estimated Company Cash, Estimated Company Debt, Estimated Working Capital as compared to the Working Capital”
Earnings Releases
CorMedix Inc. reported first quarter ended March 31, 2024 results: net income net loss of $14.5 million, EPS $0.25 per share.
“CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024”
Earnings Releases
CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.
“For the fourth quarter of 2023, CorMedix recorded a net loss of $14.8 million, or $0.26 per share”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.